FF 69:DUPLEX Sparsentan, it’s no Acthar Gel
Listen now
Description
FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?
More Episodes
We had a great NephJC get together. We recorded the whole event and packaged it into a podcast. Musical entertainment Tim Yau (@Maximal_Change) Too Sweet by Hozier Fairy Tale of New York by written Jem Finer and Shane MacGowan. Hear it performed by the Pogues. Interview of Tom Mueller Tom...
Published 11/04/24
The Filtrate: Jennie Lin Joel Topf Josh Waitzman Swapnil Hiremath With Special Guests Pedro Teixeira Jay Koyner Editor Sophia Ambruso Show Notes The article: A Randomized Trial of Intravenous Amino Acids for Kidney Protection NephJC Summary KDIGO Clinical Practice Guideline for Acute Kidney...
Published 10/18/24